42782-96-7

Upstream product

• 61263-34-1 (Z)-7-[(1R,2R,3R)-2-((E)-(R)-4,4-Dimethyl-3-trimethylsilanyloxy-oct-1-enyl)-5-oxo-3-trimethylsilanyloxy-cyclopentyl]-hept-5-enoic acid methyl ester 
• 220328-60-9 [(R)-1-((E)-2-Iodo-vinyl)-2,2-dimethyl-hexyloxy]-trimethyl-silane 
• 220328-64-3 (R)-4,4-dimethyl-1-iodo-1(E)-octen-3-ol 

Downstream Products

• 39746-25-3 16,16-dimethyl-PGE₂ 

Relevant academic research and scientific papers

Effective stereoselective total synthesis of 16,16-dimethyl prostaglandin E2

The first stereoselective synthesis of the specific EP1 receptor agonist, 16,16-dimethyl prostaglandin E2 1, is described. The key- intermediate 3 was obtained from the E-allyl alcohol 6 via Sharpless epoxidation followed by stereospecific transformations to the γ-iodo vinyl compound 3. Two component coupling of 2 and 3, using the dilithiocyanocuprate technology, gave the 1,4-addition product. Mild desilylation and enzymatic ester cleavage produced the optically pure prostaglandin 1 in high yield.

8β,12α,15β-PGF2 β Compounds

This invention is a group of 8-beta, 12-alpha-PG2 (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.